Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5

PL Ramesh, P Khandelwal, R Lakshmy, A Sinha… - Pediatric …, 2023 - Springer
Background Dyslipidemia is a potentially modifiable risk factor in patients with chronic
kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is …
被引用次数：2 相关文章

Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2–5.

PL Ramesh, P Khandelwal, R Lakshmy… - Pediatric …, 2023 - search.ebscohost.com
Background: Dyslipidemia is a potentially modifiable risk factor in patients with chronic
kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is …

Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5

PL Ramesh, P Khandelwal… - Pediatric …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Dyslipidemia is a potentially modifiable risk factor in patients with chronic
kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is …

Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.

PL Ramesh, P Khandelwal, R Lakshmy… - Pediatric Nephrology …, 2023 - europepmc.org
Background Dyslipidemia is a potentially modifiable risk factor in patients with chronic
kidney disease (CKD). Information on the safety and efficacy of statins in pediatric CKD is …